RxDoctor Payments Data

James Warr, MD

Family Medicine · Mountain Home, ARNPI 1770628471

Payments from drug & device makers

$1,132in general payments, 2019–2025

Across 71 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$261
  • Astellas Pharma US Inc$252
  • Boston Scientific$191
  • GSK$122
  • Abbott$84
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$47
  • plus $175 from 7 others

What the payments were for

  • Food & beverage$1,03491%
  • Education$989%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,132 in reported general payments places this provider in the 60th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$300,585
Medicare patients
556
Services billed
5,265

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide300$342,022
Trelegy ElliptaFluticasone/Umeclidin/Vilanter166$163,131
EliquisApixaban115$105,336
JardianceEmpagliflozin83$76,491
Xeljanz XrTofacitinib Citrate12$66,074
JanuviaSitagliptin Phosphate35$43,157
XareltoRivaroxaban58$36,748
MyrbetriqMirabegron65$33,911
RybelsusSemaglutide21$27,339
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog30$21,497
FarxigaDapagliflozin Propanediol15$21,376
CreonLipase/Protease/Amylase17$19,216
Breo ElliptaFluticasone/Vilanterol22$16,233
Tresiba Flextouch U-100Insulin Degludec27$14,796
TrulicityDulaglutide11$12,500

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$28$369,361321 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta$122$184,235199 claims
PfizerEliquis, Paxlovid$36$108,220130 claims
MerckJanuvia, Janumet Xr$16$54,41355 claims
Astellas Pharma US IncMyrbetriq$252$33,91165 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Mountain Home

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →